Day: February 9, 2022

Fluence’s AI-powered IQ Bidding Application will enable AES to maximize the value of solar and energy storage projects in the Western US ARLINGTON, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) — Fluence (Nasdaq: FLNC) today announced an agreement with The AES Corporation (NYSE: AES) to employ the AI-powered Fluence IQ Bidding Application to maximize the value of a 1.1 GW portfolio of solar and energy storage projects in the Western United States. The agreement represents one of the largest single procurements of AI-powered bidding software for renewables and storage assets by an independent power producer in the United States. The software will optimize revenues earned by solar and battery assets through participation in wholesale markets. The Fluence IQ Bidding Application recommends bids into daily and hourly auctions for energy and grid...

SUBSTANTIAL RESOURCE GROWTH OPPORTUNITIES CONFIRMEDFigure 1Calico Project Inferred Mineral Resource: Block Model of the Waterloo DepositFigure 2Calico Project Inferred Mineral Resource: Waterloo Block Model Cross SectionFigure 3Calico Project Inferred Mineral Resource: Block Model of the Langtry DepositVANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce its Maiden National Instrument (“NI”) 43-101 Mineral Resource Estimates (“MRE”) for the Waterloo and Langtry silver properties, now collectively referred to as the Calico Silver Project1 (“Calico” or the “Project”), located in San Bernardino County, California. An Inferred resource estimate of 166 million ounces...

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform. A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation. About TCR2 Therapeutics TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the...

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET. A live webcast will be available in the investor section of the company’s website at www.beamtx.com, and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies...

–FC2 Prescription Business Entering 6th Year of Growth — –FDA Approves Company’s ENTADFI™, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway– –Company Enters into Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate Enobosarm and Abemaciclib Combination in Phase 3 ENABLAR-2 Trial– — Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy in Metastatic Breast Cancer is Enrolling and Receives FDA Fast Track Designation– –Phase 3 COVID-19 Registration Program Receives FDA Fast Track Designation, Clinical Results Expected in the First Half of Calendar 2022– –Company to Host Investor Conference Call Today at 8 AM ET– MIAMI, Feb. 09, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical...

2022 revenue guidance of $140 million and forecasts $250 million in organic revenue in 3-4 years NETANYA, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) — RADA Electronic Industries Ltd. (NASDAQ: RADA, TASE: RADA) announced today its financial results for the year and quarter ended December 31, 2021. Highlights of Full Year 2021Record revenues of $117.2 million, up 54% year-over-year; Gross margin of 41% up from 37% in 2020; Net income of $25.1 million compared to $5.6 million net income in 2020; Adjusted EBITDA of $27.3 million (23% margin) compared to $9.7 million (13% margin) in 2020; Year-end net cash position of $78.8 million.Highlights of Q4 2021Quarterly revenues of $31.8 million, up 36% year-over-year; Gross margin of 41%, up from 39% in Q4 of 2020; Net income of $4.9 million compared to $2.6 million net income in Q4 of 2020; Adjusted...